United Therapeutics Corporation (UTHR) Operating Cash Flow CAGR:10.73%(TTM)
Operating cash flow CAGR uses precomputed cash-flow statement history (cash from operations, before capital expenditures).
Over longer horizons, United Therapeutics Corporation's Operating Cash Flow CAGR averages 20.71% over 3 years and 19.90% over 5 years.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. Operating cash flow CAGR measures the compound annual growth rate of the cash United Therapeutics Corporation generates from its core business operations, before capital expenditures, computed from rolling-twelve-month cash-flow statement history.
UTHR Operating Cash Flow CAGR Chart
United Therapeutics Corporation (UTHR)
UTHR Quarterly Operating Cash Flow Growth (YoY)
Operating Cash Flow growth vs the same quarter one year earlier, last 20 quarters.
UTHR Operating Cash Flow CAGR History
| Year | Start OCF | End OCF | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $1.33B | $1.56B | +$234.10M | +17.64% | +17.64% |
| 2024 | $978.00M | $1.33B | +$349.10M | +35.70% | +35.70% |
| 2023 | $802.50M | $978.00M | +$175.50M | +21.87% | +21.87% |
| 2022 | $598.20M | $802.50M | +$204.30M | +34.15% | +34.15% |
| 2021 | $755.70M | $598.20M | $-157.50M | -20.84% | -20.84% |
| 2020 | $-206.60M | $755.70M | +$962.30M | N/A | N/A |
| 2019 | $778.40M | $-206.60M | $-985.00M | -126.54% | N/A |
| 2018 | $474.20M | $778.40M | +$304.20M | +64.15% | +64.15% |
| 2017 | $643.60M | $474.20M | $-169.40M | -26.32% | -26.32% |
| 2016 | $382.80M | $643.60M | +$260.80M | +68.13% | +68.13% |
| 2015 | $355.30M | $382.80M | +$27.50M | +7.74% | +7.74% |
| 2014 | $425.27M | $355.30M | $-69.97M | -16.45% | -16.45% |
| 2013 | $323.63M | $425.27M | +$101.64M | +31.41% | +31.41% |
| 2012 | $250.19M | $323.63M | +$73.43M | +29.35% | +29.35% |
| 2011 | $211.53M | $250.19M | +$38.66M | +18.28% | +18.28% |
| 2010 | $97.62M | $211.53M | +$113.91M | +116.68% | +116.68% |
| 2009 | $-49.17M | $97.62M | +$146.80M | N/A | N/A |
| 2008 | $49.08M | $-49.17M | $-98.25M | -200.18% | N/A |
| 2007 | $51.78M | $49.08M | $-2.70M | -5.22% | -5.22% |
| 2006 | $43.70M | $51.78M | +$8.08M | +18.50% | +18.50% |
| 2005 | $20.78M | $43.70M | +$22.92M | +110.32% | +110.32% |
| 2004 | $-8.56M | $20.78M | +$29.34M | N/A | N/A |
| 2003 | $-22.26M | $-8.56M | +$13.70M | N/A | N/A |
| 2002 | $-38.90M | $-22.26M | +$16.64M | N/A | N/A |
| 2001 | $-31.11M | $-38.90M | $-7.78M | N/A | N/A |
| 2000 | $-23.70M | $-31.11M | $-7.41M | N/A | N/A |
| 1999 | $-9.60M | $-23.70M | $-14.10M | N/A | N/A |
Quarterly Operating Cash Flow: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2026 | $463.30M | +33.8% | +0.5% |
| Q4 2025 | $346.20M | -38.4% | +1.5% |
| Q3 2025 | $562.10M | +193.2% | +49.0% |
| Q2 2025 | $191.70M | -58.4% | -17.4% |
| Q1 2025 | $461.20M | +35.2% | +22.5% |
| Q4 2024 | $341.20M | -9.5% | +126.4% |
| Q3 2024 | $377.20M | +62.4% | +9.0% |
| Q2 2024 | $232.20M | -38.3% | +118.4% |
| Q1 2024 | $376.50M | +149.8% | +0.5% |
| Q4 2023 | $150.70M | -56.5% | +17.6% |
| Q3 2023 | $346.20M | +225.7% | +33.9% |
| Q2 2023 | $106.30M | -71.6% | -16.3% |
| Q1 2023 | $374.80M | +192.4% | +29.8% |
| Q4 2022 | $128.20M | -50.4% | -26.6% |
| Q3 2022 | $258.60M | +103.6% | +39.3% |
| Q2 2022 | $127.00M | -56.0% | -14.3% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About United Therapeutics Corporation
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Martine A. Rothblatt